Phase I Study of Patritumab Deruxtecan in Patients With EGFR-Mutated NSCLC and Resistance to EGFR TKI Therapy

June 4-8, 2021; Online at https://conferences.asco.org/am
Updated phase I results with extended follow-up show antitumor activity of patritumab deruxtecan in patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC across various EGFR TKI resistance mechanisms and regardless of prior therapy or presence of CNS metastases.
Format: Microsoft PowerPoint (.ppt)
File Size: 467 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Phase I/II trial of mobocertinib for EGFR ex20ins+ advanced NSCLC in cohort of patients with disease progression after initial disease control on EGFR TKI therapy, from WCLC 2021 by Clinical Care Options (CCO)

Released: September 23, 2021

Initial analysis of amivantamab in patients with METex14+ metastatic or unresectable NSCLC from phase I CHRYSALIS trial, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 23, 2021

Downloadable summary slideset from a live CCO Webinar on immunotherapy for the treatment of patients across the spectrum of NSCLC

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 23, 2021

3-year update of CASPIAN showed sustained survival benefit of adding durvalumab to platinum-etoposide for first-line treatment in extensive-stage SCLC, presented at ESMO 2021 and reported by Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue